Literature DB >> 29694628

Papillary thyroid microcarcinoma: characteristics at presentation, and evaluation of clinical and histological features associated with a worse prognosis in a Latin American cohort.

José M Domínguez1, Flavia Nilo1, María T Martínez1, José M Massardo1, Sueli Muñoz1, Tania Contreras1, Rocío Carmona1, Joaquín Jerez1, Hernán González2, Nicolás Droppelmann2, Augusto León2.   

Abstract

Objective We aimed to describe the presentation of papillary microcarcinoma (PTMC) and identify the clinical and histological features associated with persistence/recurrence in a Latin American cohort. Subjects and methods Retrospective study of PTMC patients who underwent total thyroidectomy, with or without radioactive iodine (RAI), and who were followed for at least 2 years. Risk of recurrence was estimated with ATA 2009 and 2015 classifications, and risk of mortality with 7th and 8th AJCC/TNM systems. Clinical data obtained during follow-up were used to detect structural and biochemical persistence/recurrence. Results We included 209 patients, predominantly female (90%), 44.5 ± 12.6 years old, 183 (88%) received RAI (90.4 ± 44.2 mCi), followed-up for a median of 4.4 years (range 2.0-7.8). The 7th and 8th AJCC/TNM system classified 89% and 95.2% of the patients as stage I, respectively. ATA 2009 and ATA 2015 classified 70.8% and 78.5% of the patients as low risk, respectively. Fifteen (7%) patients had persistence/recurrence during follow-up. In multivariate analysis, only lymph node metastasis was associated with persistence/recurrence (coefficient beta 4.0, p = 0.016; 95% CI 1.3-12.9). There were no PTMC related deaths. Conclusions Our series found no mortality and low rate of persistence/recurrence associated with PTMC. Lymph node metastasis was the only feature associated with recurrence in multivariate analysis. The updated ATA 2015 and 8th AJCC/TNM systems classified more PTMCs than previous classifications as low risk of recurrence and mortality, respectively.

Entities:  

Mesh:

Year:  2018        PMID: 29694628     DOI: 10.20945/2359-3997000000013

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  5 in total

1.  Incidentally discovered papillary thyroid microcarcinoma in patients undergoing thyroid surgery for benign disease.

Authors:  Joaquín de Carlos; Ander Ernaga; Ana Irigaray; Jose Javier Pineda; Ana Echegoyen; Pilar Salvador; Emma Anda
Journal:  Endocrine       Date:  2022-05-31       Impact factor: 3.925

2.  A Radiomic Nomogram for the Ultrasound-Based Evaluation of Extrathyroidal Extension in Papillary Thyroid Carcinoma.

Authors:  Xian Wang; Enock Adjei Agyekum; Yongzhen Ren; Jin Zhang; Qing Zhang; Hui Sun; Guoliang Zhang; Feiju Xu; Xiangshu Bo; Wenzhi Lv; Shudong Hu; Xiaoqin Qian
Journal:  Front Oncol       Date:  2021-03-04       Impact factor: 6.244

3.  Characteristics and Management of Papillary Thyroid Microcarcinoma in the United Arab Emirates: Experience from a Large Tertiary Hospital.

Authors:  Azhar A Malik; Faisal Aziz; Salem A Beshyah; Khaled M Aldahmani
Journal:  Saudi J Med Med Sci       Date:  2022-01-17

4.  Evaluation of surgical risk and prognosis between thyroid nodules of size <1 and ≥1 cm.

Authors:  Jia-Min Ma; Lin-Feng Wu; Ji-Sheng Hu; Zong-Wen Zhu; Guang-Zhou Li; Guo-Qing Li; Bei Sun; Gang Wang
Journal:  Gland Surg       Date:  2019-12

5.  Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy.

Authors:  Canhua Yun; Meiling Wu; Juan Xiao; Yong Liu; Wei Zhang; Jingjia Cao
Journal:  Cancer Manag Res       Date:  2021-02-12       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.